Heart substructural dosimetric parameters and risk of cardiac events after definitive chemoradiotherapy for stage III non-small cell lung cancer.

CONCLUSIONS: A high LV radiation dose could increase ACS events in patients with stage III NSCLC and high cardiovascular risk. Pre-treatment cardiac risk evaluation and individualized surveillance may help prevent cardiac events after chemoradiotherapy.
PMID: 33058951 [PubMed - as supplied by publisher]

Source: Radiotherapy and Oncology : journal of the European Society for Therapeutic Radiology and Oncology - October 12, 2020 Category: Radiology Authors: Jang BS, Cha MJ, Kim HJ, Oh S, Wu HG, Kim E, Kim BH, Kim JS, Chang JH Tags: Radiother Oncol Source Type: research